Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Recommendation of “Moderate Buy” from Analysts

Twist Bioscience Corporation (NASDAQ:TWST) has earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $48.50.

TWST has been the topic of several research analyst reports. Evercore ISI cut their price objective on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Barclays cut their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday.

Insider Activity at Twist Bioscience

In related news, CAO Robert F. Werner sold 2,041 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $65,699.79. Following the sale, the chief accounting officer directly owned 46,413 shares in the company, valued at approximately $1,494,034.47. This represents a 4.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 31,348 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $1,009,092.12. Following the sale, the chief executive officer owned 601,212 shares in the company, valued at $19,353,014.28. The trade was a 4.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,851 shares of company stock worth $1,859,894 over the last quarter. 3.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of TWST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after buying an additional 1,588,587 shares during the last quarter. EdgePoint Investment Group Inc. increased its holdings in shares of Twist Bioscience by 114.3% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 2,385,942 shares of the company’s stock valued at $87,779,000 after acquiring an additional 1,272,732 shares during the last quarter. Nuveen LLC purchased a new position in shares of Twist Bioscience in the 1st quarter valued at about $31,960,000. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock valued at $245,045,000 after acquiring an additional 645,730 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in shares of Twist Bioscience by 934.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock valued at $23,113,000 after acquiring an additional 567,481 shares during the last quarter.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $31.89 on Friday. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -21.99 and a beta of 2.38. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience has a 1 year low of $24.07 and a 1 year high of $55.33. The company’s 50 day simple moving average is $27.68 and its 200-day simple moving average is $32.75.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.